Somatic RNA variant calling in solid tumors
About Gene fusions are the latest type of biomarker to receive broad applicability in cancer management. More than 10,000 gene fusions have already been identified in human cancers and it is estimated that up to 80% of solid tumors could benefit from gene fusion...
White Paper: Performance Evaluation of the CE-IVD SOPHiA DDM™️ Dx RNAtarget Oncology Solution (ROS)
Read our SOPHiA DDM™️ Dx ROS performance evaluation study and make confident data-driven decisions that improve patient care.
Raising Awareness of Familial Hypercholesterolemia (FH)
Studies show that as few as 10% of people living with familial hypercholesterolemia (FH) could be aware of their diagnosis. Could genetic testing expedite early diagnosis and timely treatment?
Food for thought from ESMO 2022: the journey towards personalized therapy
Last week we attended the European Society for Medical Oncology (ESMO) Congress 2022, gathering the world's leading oncologists. Read our summary of three presentations illustrating cancer therapy development.
SOPHiA GENETICS Unveils Strategy to Drive Health Care Innovations at Inaugural Investor Day Event
Highlights include: a memorandum of understanding with Memorial Sloan Kettering Cancer Center and a novel new partnership with Boundless Bio, a next-generation precision oncology company SOPHiA GENETICS’ next-generation solution CarePath, fueled by current real...
World GO Day Raising Awareness for Gynaecological Cancers
With over 1.3 million women worldwide diagnosed with gynaecological cancers in 2020, it’s more important now than ever to equip them with tools and resources to promote prevention and early detection of potential cancers.
SOPHiA GENETICS to Participate in Fireside Chat at 20th Annual Morgan Stanley Global Healthcare Conference
BOSTON and LAUSANNE, Switzerland, Sept. 02, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, announced today Chief Executive Officer, Dr. Jurgi Camblong and Chief Financial Officer, Ross Muken will...
Summer 2022 Newsletter
Attend/Stream the EventOur first-ever Investor Day is on September 20th in NYC! We'll be streaming live as our execs discuss the latest news and innovations in our journey to...
The Launch of SOPHiA DDM™ Dispatch
SOPHiA GENETICS is excited to announce the launch of SOPHiA DDM™ Dispatch, a new way for our SOPHiA GENETICS Integrated Access partner labs to work with their clients. SOPHiA DDM™ Dispatch make its it easier to work with clients directly and control logistics within your lab.
Considerations for whole exome sequencing
Whole exome sequencing can present a goldilocks option between targeted gene panels and whole genome sequencing. Dive into some of the considerations for adopting whole exome sequencing in your institution.
SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2022
Steady Operational Performance Amidst Macroeconomic Headwinds BOSTON and LAUSANNE, Switzerland, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today reported financial results for the...
SOPHiA GENETICS to Host Investor Day on September 20, 2022, in New York City
BOSTON and LAUSANNE, Switzerland, Aug. 04, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, announced today it will host its first-ever Investor Day on Tuesday, September 20, 2022, at PUBLIC Hotel...
Partner Spotlight: Dr Alessandra Terracciano
Read about our successful collaborations, Dr Terracciano’s favorite SOPHiA DDM™ features, and what she sees in the future for SOPHiA GENETICS.
SOPHiA GENETICS to Participate in Canaccord Genuity 42nd Annual Growth Conference
BOSTON and LAUSANNE, Switzerland, July 29, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, announced today Chief Financial Officer, Ross Muken, will attend and be a panelist at the Canaccord Genuity 42nd Annual...
SOPHiA GENETICS to Announce Financial Results for the Second Quarter of Fiscal 2022 on August 9, 2022
BOSTON and LAUSANNE, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the second quarter of fiscal 2022 before U.S. markets open on...
